Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study

European Journal of Heart Failure

Volumn 18, Issue 9, 2016, Pages 1175-1181

  Chin, Ken Lee ^a   Collier, Timothy J ^b   Pitt, Bertram ^c   McMurray, John J V ^d   Swedberg, Karl ^e,f   van Veldhuisen, Dirk J ^g   Pocock, Stuart J ^b   Vincent, John ^h   Turgonyi, Eva ^h   Zannad, Faiez ⁱ   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h PFIZER INC   (United States)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Aldosterone; Aspirin; Bradykinin; Eplerenone; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; MINERALOCORTICOID ANTAGONIST; PLACEBO;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

EID: 84985940539     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.485     Document Type: Article

References (25)

1. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Trial. J Am Coll Cardiol 1998;31:419–425.
2. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115–119.
3. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown J, Edward J., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction—results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669–677.
4. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.
5. Aumégeat V, Lamblin N, De Groote P, Mc Fadden EP, Millaire A, Bauters C, Lablanche J-M. Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with angiotensin-converting enzyme inhibitors. Chest 2003;124:1250–1258.
6. Masoudi FA, Wolfe P, Havranek EP, Rathore SS, Foody JM, Krumholz HM. Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. J Am Coll Cardiol 2005;46:955– 962.
7. Teo KK, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, Latini R, Collins R, for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037–1043.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–717.
9. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, for the EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425–431.
10. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock S, Pitt B, for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
11. Papanicolaou N, Lefkos N, Massourides E, Marketos S, Papavassiliou J, Bariety J, Milliez P. Interaction between aldosterone and renomedullary prostaglandins. Competitive action between aspirin and spironolactone. Experientia 1977;33:1632–1635.
12. Tweeddale MG, Ogilvie RI. Antagonism of spironolactone-induced natriuresis by aspirin in man. N Engl J Med 1973;289::198–200.
13. Ramsay LE, Harrison IR, Shelton JR, Vose CW. Influence of acetylsalicylic acid on the renal handling of a spironolactone metabolite in healthy subjects. Eur J Clin Pharmacol 1976;10:43–48.
14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.
15. Zannad F, McMurray JJV, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617–622.
16. Collier TJ, Pocock SJ, McMurray JJV, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013;34:2823–2829.
17. Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med 2000;160:1409–1413.
18. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure—relation to activation of the renin–angiotensin system and hyponatremia. N Engl J Med 1984;310:347–352.
19. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, on behalf of the PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16:817–825.
20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
22. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, on behalf of the EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118:1643–1650.
23. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L, on behalf of the PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544–554.
24. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin–angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 2003;163:1574–1579.
25. Meune C, Mahé I, Mourad J-J, Cohen-Solal A, Levy B, Kevorkian J-P, Jondeau G, Habib A, Lebret M, Knellwolf A-L, Simoneau G, Caulin C, Bergmann J-F. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail 2003;5: 271–279.